<DOC>
	<DOCNO>NCT00661505</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability once-monthly administration intravenous Mircera maintenance hemoglobin level hemodialysis patient chronic renal anemia . Patients receive 4-weekly intravenous injection Mircera , start dose 120 , 200 360 microgram . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Hemodialysis Patients With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; = 18 year age ; chronic renal anemia ; continuous stable iv sc maintenance epoetin therapy previous 4 week ; regular longterm hemodialysis therapy mode dialysis previous 3 month . transfusion red blood cell previous 2 month ; poorly control hypertension require hospitalization interruption epoetin treatment previous 6 month ; significant acute chronic bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>